News & Events

November 12, 2024

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications

July 22, 2024

Apollo Therapeutics and the University of Oxford enter into drug discovery and development collaboration

Apollo Therapeutics will inject capital and expertise into pipeline of potentially lifesaving medici

January 02, 2024

Apollo Therapeutics Announces Second Close Of Series C Financing Bringing Total Raised In Round To $260 Million

September 06, 2023

Apollo Therapeutics Closes $226.5 Million Series C Financing Led by Patient Square Capital

November 14, 2022

Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development

ICR joins University of Cambridge, Imperial College London, UCL and King’s College London as a str

August 01, 2022

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

February 22, 2022

Apollo Therapeutics and King’s College London enter into a strategic collaboration

Apollo grows its partnerships with world-leading research institutions in the UK, with King’s join

November 18, 2021

Apollo Therapeutics Appoints Dr. Sanjay Aggarwal as Chief Medical Officer, Opens U.S. Facility

June 17, 2021

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Adv